Page last updated: 2024-10-30

leflunomide and Abnormalities, Drug-Induced

leflunomide has been researched along with Abnormalities, Drug-Induced in 14 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.

Research Excerpts

ExcerptRelevanceReference
"Maternal exposure to leflunomide during pregnancy was not associated with statistically significant increased risk of MCMs, prematurity, LBW or spontaneous abortions."7.88Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. ( Bérard, A; Colilla, S; Shui, I; Zhao, JP, 2018)
"All 16 of the pregnancies with leflunomide exposure during pregnancy and 27 (93%) of the pregnancies with exposure prior to conception resulted in liveborn infants."7.78Pregnancy outcome in women exposed to leflunomide before or during pregnancy. ( Braddock, SR; Cassina, M; Chambers, CD; Jimenez, JL; Johnson, DL; Jones, KL; Luo, YJ; Mirrasoul, N; Robinson, LK; Salas, E; Xu, R, 2012)
"Leflunomide is a new and effective disease-modifying antirheumatic drug."5.31Leflunomide: new antirheumatic drug. Effect on pregnancy outcomes. ( Koren, G; Kozer, E; Moretti, ME, 2001)
"The widely accepted standard therapy for cutaneous sarcoidosis includes corticosteroids, antimalarials, and methotrexate."4.84Cutaneous sarcoidosis therapy updated. ( Badgwell, C; Rosen, T, 2007)
"Maternal exposure to leflunomide during pregnancy was not associated with statistically significant increased risk of MCMs, prematurity, LBW or spontaneous abortions."3.88Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. ( Bérard, A; Colilla, S; Shui, I; Zhao, JP, 2018)
"All 16 of the pregnancies with leflunomide exposure during pregnancy and 27 (93%) of the pregnancies with exposure prior to conception resulted in liveborn infants."3.78Pregnancy outcome in women exposed to leflunomide before or during pregnancy. ( Braddock, SR; Cassina, M; Chambers, CD; Jimenez, JL; Johnson, DL; Jones, KL; Luo, YJ; Mirrasoul, N; Robinson, LK; Salas, E; Xu, R, 2012)
"Leflunomide is an immunosuppressant drug displaying teratogenicity in mice, rats, and rabbits."1.35Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine. ( Fukushima, R; Hirashiba, M; Hishikawa, A; Kanamori, S; Kaneto, M; Kitagawa, H; Muranaka, R, 2009)
"Leflunomide has inhibitory effects on dihydroorotate-dehydrogenase activity and protein tyrosine kinase activity."1.35Critical periods for the teratogenicity of immune-suppressant Leflunomide in mice. ( Fukushima, R; Hirashiba, M; Hishikawa, A; Kanamori, S; Kaneto, M; Kitagawa, H; Muranaka, R, 2009)
"Leflunomide is a new and effective disease-modifying antirheumatic drug."1.31Leflunomide: new antirheumatic drug. Effect on pregnancy outcomes. ( Koren, G; Kozer, E; Moretti, ME, 2001)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (42.86)29.6817
2010's6 (42.86)24.3611
2020's2 (14.29)2.80

Authors

AuthorsStudies
Pfaller, B1
Pupco, A1
Leibson, T1
Aletaha, D1
Ito, S1
Hammad, I1
Porter, TF1
Weber-Schoendorfer, C1
Beck, E1
Tissen-Diabaté, T1
Schaefer, C1
Bérard, A1
Zhao, JP1
Shui, I1
Colilla, S1
Cassina, M2
Cagnoli, GA1
Zuccarello, D1
Di Gianantonio, E1
Clementi, M1
Fukushima, R2
Kanamori, S2
Hirashiba, M2
Hishikawa, A2
Muranaka, R2
Kaneto, M2
Kitagawa, H2
Chambers, CD3
Johnson, DL2
Robinson, LK1
Braddock, SR1
Xu, R1
Jimenez, JL1
Mirrasoul, N1
Salas, E1
Luo, YJ1
Jones, KL2
Viktil, KK1
Engeland, A1
Furu, K1
Badgwell, C1
Rosen, T1
Chambers, C1
Koren, G2
Tutuncu, ZN1
Johnson, D1
Kozer, E1
Moretti, ME1
Lyons Jones, K1

Reviews

4 reviews available for leflunomide and Abnormalities, Drug-Induced

ArticleYear
A critical review of the reproductive safety of Leflunomide.
    Clinical rheumatology, 2020, Volume: 39, Issue:2

    Topics: Abnormalities, Drug-Induced; Animals; Female; Humans; Immunosuppressive Agents; Leflunomide; Pregnan

2020
An Update on Biologic Agents During Pregnancy.
    Clinics in perinatology, 2020, Volume: 47, Issue:4

    Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humani

2020
Cutaneous sarcoidosis therapy updated.
    Journal of the American Academy of Dermatology, 2007, Volume: 56, Issue:1

    Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Allopurinol; Animals; Anti-Inflammatory Agents

2007
Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study.
    Canadian family physician Medecin de famille canadien, 2007, Volume: 53, Issue:3

    Topics: Abnormalities, Drug-Induced; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprin

2007

Other Studies

10 other studies available for leflunomide and Abnormalities, Drug-Induced

ArticleYear
Leflunomide - A human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database.
    Reproductive toxicology (Elmsford, N.Y.), 2017, Volume: 71

    Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adolescent; Adult; Adverse Drug Reaction Reporti

2017
Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes.
    Annals of the rheumatic diseases, 2018, Volume: 77, Issue:4

    Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Humans; Inf

2018
Human teratogens and genetic phenocopies. Understanding pathogenesis through human genes mutation.
    European journal of medical genetics, 2017, Volume: 60, Issue:1

    Topics: Abnormalities, Drug-Induced; Angiotensin-Converting Enzyme Inhibitors; Animals; Female; Fetal Diseas

2017
Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine.
    Toxicological sciences : an official journal of the Society of Toxicology, 2009, Volume: 108, Issue:2

    Topics: Abnormalities, Drug-Induced; Animals; Dihydroorotate Dehydrogenase; Embryonic Development; Female; F

2009
Critical periods for the teratogenicity of immune-suppressant Leflunomide in mice.
    Congenital anomalies, 2009, Volume: 49, Issue:1

    Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adjuvants, Immunologic; Animals; Critical Peri

2009
Value of the small cohort study including a physical examination for minor structural defects in identifying new human teratogens.
    Congenital anomalies, 2011, Volume: 51, Issue:1

    Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antidepressive Agents; Arthritis, Rheumatoid; Carbamaz

2011
Pregnancy outcome in women exposed to leflunomide before or during pregnancy.
    Arthritis and rheumatism, 2012, Volume: 64, Issue:7

    Topics: Abnormalities, Drug-Induced; Antirheumatic Agents; Chondrodysplasia Punctata; Ductus Arteriosus, Pat

2012
Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers.
    Scandinavian journal of rheumatology, 2012, Volume: 41, Issue:3

    Topics: Abnormalities, Drug-Induced; Adalimumab; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antir

2012
Leflunomide: new antirheumatic drug. Effect on pregnancy outcomes.
    Canadian family physician Medecin de famille canadien, 2001, Volume: 47

    Topics: Abnormalities, Drug-Induced; Adult; Arthritis, Rheumatoid; Female; Half-Life; Humans; Immunosuppress

2001
Monitoring leflunomide (Arava) as a new potential teratogen.
    Teratology, 2002, Volume: 65, Issue:5

    Topics: Abnormalities, Drug-Induced; Arthritis, Rheumatoid; Female; Humans; Infant, Newborn; Isoxazoles; Lef

2002